Biotech for less than cash value Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than cash value

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (65)	7/10/2002 8:48:59 AM
From: Hank	Read Replies (2) of 684

VPHM is dead meat. Pleconaril was NEVER a good drug. It doesn't work equally well against the majority of rhinoviruses and it only reduces the duration of a cold by a couple of days. Even if it had been approved, it would never have been a big money maker since the only reasonable application for it is for the elderly and people with weakened immune systems. Furthermore, this drug was patented over 8 years ago. Even if by some miracle they do several more years of clinical trials and finally get it approved for treatment of picornavirus infection, they will only have 10 years or less to make any money before patent expiration. What other drugs do they have? Nothing. Their focus on RNA viruses is way too narrow and depended entirely on pleconaril's success. All of the potential targets for RNA viruses have been thoroughly investigated by big pharma and they haven't come up with squat. What makes you think VPHM can do better?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next